University of Toronto and the UT Innovations Foundation
This article was originally published in Start Up
Eight years ago, the University of Toronto and the Innovations Foundation instituted a new policy that offered to give up ownership of most technologies to the researchers who invented them, in return for a 25% cut of the researchers' proceeds. The results of the UT's ownership policy and the IF's reorganization have been dramatic; today, UT researchers disclose about 120 inventions a year, roughly two-thirds of them medically related.
You may also be interested in...
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.
Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.